Incyte Names New Member to Its Board of Directors
September 28 2021 - 5:00PM
Business Wire
Incyte (Nasdaq:INCY) announces the appointment of Otis Brawley,
M.D., as a new member of its Board of Directors, effective
September 27, 2021.
“We are very pleased to welcome Otis to the Incyte Board of
Directors. His distinguished career and extensive clinical
experience will be a great addition to our Board and we expect he
will contribute greatly to our continued success in the future,”
said Hervé Hoppenot, Chief Executive Officer, Incyte.
“As part of the Incyte Board, I join a very experienced and
diverse team dedicated to scientific discovery and to the
development of new, innovative medicines for patients. I am excited
for this opportunity, and look forward to participating in the
leadership of this dynamic Company,” said Dr. Brawley.
Since 2019, Dr. Brawley has served as a Bloomberg Distinguished
Professor of Oncology and Epidemiology at Johns Hopkins University.
Prior to his current position at Johns Hopkins, Dr. Brawley was the
Chief Medical and Scientific Officer of the American Cancer Society
from 2007 to 2018, and director of the Georgia Cancer Center at
Grady Memorial Hospital from 2002 to 2007. From 2001 to 2018, Dr.
Brawley was also a Professor of Hematology, Oncology, Medicine and
Epidemiology at Emory University. Prior to joining Emory, Dr.
Brawley was an Assistant Director and Senior Investigator at the
National Cancer Institute and an Internist and Oncologist at the
National Institutes of Health Clinical Center and Bethesda Naval
Hospital. Dr. Brawley is also a member of the boards of directors
of Lyell Immunopharma, Inc. and PDS Biotechnology Corporation.
About Incyte Incyte is a
Wilmington, Delaware-based, global biopharmaceutical company
focused on finding solutions for serious unmet medical needs
through the discovery, development and commercialization of
proprietary therapeutics. For additional information on Incyte,
please visit Incyte.com and follow @Incyte.
Forward-Looking Statements
Except for the historical information set forth herein, the matters
set forth in this press release contain predictions, estimates and
other forward-looking statements. These forward-looking statements
are based on the Company’s current expectations and subject to
risks and uncertainties that may cause actual results to differ
materially, including risks related to market competition, the
results of and risks associated with research and development,
risks and uncertainties associated with sales, marketing and
distribution requirements, and other risks detailed from time to
time in the Company’s reports filed with the Securities and
Exchange Commission, including its annual report and its quarterly
report on Form 10-Q for the quarter ended June 30, 2021. Incyte
disclaims any intent or obligation to update these forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210928006095/en/
Media Catalina Loveman +1 302 498 6171
cloveman@incyte.com
Investors Christine Chiou +1 302 274 4773
cchiou@incyte.com
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Jul 2023 to Jul 2024